Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorac Cancer
Hauptverfasser: Tang, Kejing, Jiang, Neng, Kuang, Yukun, He, Qiong, Li, Shuhua, Luo, Jiping, Jiang, Wenting, Chen, Yangshan, Sun, Yu, Chen, Lili, Chen, Yanyang, Zhu, Junfeng, Cui, Yongmei, Wan, Han, Ke, Zunfu
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons Australia, Ltd 2018
Schlagworte:
Case Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://ncbi.nlm.nih.gov/pubmed/30521113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12927
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge